PSPedro G. Santiago-Cardona

Pedro G. Santiago-Cardona

*This is an algorithmically generated author record based on publicly available information.

Pedro G. Santiago-Cardona has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Cabán-Rivera

    Ponce Health Sciences University-Ponce Research Institute

    3 shared publications
  • Bernadette Sosa-García

    Department of Basic Sciences, Biochemistry Division, Ponce Health Science University, Ponce, Puerto Rico

    2 shared publications
  • Camille Chardón-Colón

    Ponce Health Sciences University-Ponce Research Institute

    2 shared publications
  • Jaileene Pérez-Morales

    Ponce Health Sciences University-Ponce Research Institute

    2 shared publications
  • Jonathan González-Flores

    Biochemistry and Cancer Biology Divisions, Basic Science Department, Ponce Health Sciences University-Ponce Research Institute, Ponce, Puerto Rico

    2 shared publications
  • Viviana Vázquez-Rivera

    Department of Basic Sciences, Biochemistry Division, Ponce Health Science University, Ponce, Puerto Rico

    2 shared publications

Latest Publications

  • Open Access

    Biomarkers for Prostate Cancer Aggressiveness in Puerto Rican Men: Analysis of Phospho-Rb S249, N-cadherin, β-catenin, and E-cadherin Expression in Prostate Biopsies

    by Sheila M. Valle Cortés, Jaileene Pérez Morales, Mariely Nieves Plaza, Raymond Quiñones Alvarado, Gilberto Ruiz Deyá, Juan C. Santa Rosario, Pedro Santiago Cardona

    Prostate cancer (PCa) is the leading cause of cancer in Puerto Rican men and exhibits significant racial disparities globally. Although only 8% of cases invade beyond the prostate, predicting PCa aggressiveness is challenging. This study investigated the potential of the retinoblastoma tumor suppressor protein phosphorylated in Serine 249 (Phospho-Rb S249), N-cadherin, β-catenin, and E-cadherin as biomarkers for identifying aggressive PCa in Puerto Rican men. We hypothesized that the expression of these proteins could serve as biomarkers for identifying PCa tumors with potential to becoming aggressive in Puerto Rican men. Immunohistochemistry was performed on 23 biopsies from Puerto Rican men to evaluate the biomarkers’ expression, and correlation analyses examined associations with clinicopathological parameters. Results showed that Phospho-Rb S249 expression correlated positively with tumor size and positive cores in patients with Gleason scores ≥4+3. β-catenin was positively associated with tumor size and carcinoma percentage in Gleason scores >4+3. E-cadherin expression negatively correlated with grade group, indicating a protective role. In contrast, N-cadherin and β-catenin were more prominent in Gleason scores <3+4, hinting at their involvement in early epithelial-to-mesenchymal transition (EMT). A decision tree analysis identified N-cadherin expression as a key determinant for classifying PCa aggressiveness, with an 82% likelihood. These findings suggest N-cadherin as a biomarker for identifying PCa with the potential to become aggressive. While our study provides promising results, further validation in a larger patient cohort is needed to increase the robustness and reliability of our findings. Also, combining multiple biomarkers could further enhance the specificity of aggressive PCa detection.

  • Open Access

    Calcium Sulfide Nanoclusters Trigger DNA Damage and Induce Cell Cycle Arrest in Non-Small-Cell Lung Adenocarcinoma Cells

    by María M. Figueroa Rosado, Kevin Muñoz Forti, Patricia Rodríguez-Rodríguez, Gerardo Arroyo-Martínez, Valerie J. Rodríguez-Irizarry, Abigail Ruiz-Rivera, Jailenne I. Quinones-Rodriguez, Pedro G. Santiago-Cardona, Olga M. Rodriguez Martinez, Sharilyn Almodovar, et al.

    Lung cancer remains the most common malignancy independent of sex. Here, we focused on unraveling the molecular mechanisms of CaS nanoclusters inducing cytotoxicity by investigating DNA damage, the cell cycle, oxidative stress, and cellular repair mechanisms in non-small-cell lung carcinoma (NSCLC) cells compared to healthy lung fibroblasts. Our previous studies have demonstrated the therapeutic potential of calcium sulfide (CaS) nanostructures in skin and breast cancer models, leading to a significant reduction in cancer cell proliferation. However, how CaS nanoclusters enhance their therapeutic effects on cancer cells while minimizing damage to healthy cells remains unknown. Our results show that CaS nanoclusters, once dissociated into Ca2+ and H2S in an acidic microenvironment, selectively allow extracellular calcium to enter, leading to an increase in free calcium entry, triggering oxidative stress and limiting DNA repair mechanisms in NSCLC. Furthermore, CaS nanoclusters selectively arrest NSCLC cells in the G0-G1 and S phases of the cell cycle without affecting healthy cells’ cycles. Here, we also show that the selective effects of CaS nanoclusters on lung adenocarcinoma are less likely to be regulated by intrinsic apoptotic or mitochondrial pathways. They are, rather, caused by an increase in Ca2+ and ROS, causing double-stranded DNA breakages. This selectivity for malignant cells is pH-dependent because it occurs in the acidic microenvironment characteristic of these cells. Overall, this is the first piece of evidence that CaS disrupts genomic stability, prevents the replication of damaged cells, and ultimately influences cell fate decisions such as cell cycle arrest or cell death including mitotic catastrophe and necroptotic simultaneous events.


  • Open Access

    Integrating Proteomic Analysis and Machine Learning to Predict Prostate Cancer Aggressiveness

    by Sheila M. Valle Cortés, Jaileene Pérez Morales, Mariely Nieves Plaza, Darielys Maldonado, Swizel M. Tevenal Baez, Marc A. Negrón Blas, Cayetana Lazcano Etchebarne, José Feliciano, Gilberto Ruiz Deyá, Juan C. Santa Rosario, et al.

    Prostate cancer (PCa) poses a significant challenge because of the difficulty in identifying aggressive tumors, leading to overtreatment and missed personalized therapies. Although only 8% of cases progress beyond the prostate, the accurate prediction of aggressiveness remains crucial. Thus, this study focused on studying retinoblastoma phosphorylated at Serine 249 (Phospho-Rb S249), N-cadherin, β-catenin, and E-cadherin as biomarkers for identifying aggressive PCa using a logistic regression model and a classification and regression tree (CART). Using immunohistochemistry (IHC), we targeted the expression of these biomarkers in PCa tissues and correlated their expression with clinicopathological data of the tumor. The results showed a negative correlation between E-cadherin and β-catenin with aggressive tumor behavior, whereas Phospho-Rb S249 and N-cadherin positively correlated with increased tumor aggressiveness. Furthermore, patients were stratified based on Gleason scores and E-cadherin staining patterns to evaluate their capability for early identification of aggressive PCa. Our findings suggest that the classification tree is the most effective method for measuring the utility of these biomarkers in clinical practice, incorporating β-catenin, tumor grade, and Gleason grade as relevant determinants for identifying patients with Gleason scores ≥ 4 + 3. This study could potentially benefit patients with aggressive PCa by enabling early disease detection and closer monitoring.

  • Immunoblot Validation of Phospho-Specific Antibodies Using Lung Cancer Cell Lines

    by Wilfredo M. Pedreira-García, Jaileene Pérez-Morales, Camille Chardón-Colón, Jennifer Cabán-Rivera, Pedro G. Santiago-Cardona

    The cancer phenotype is usually characterized by deregulated activity of a variety of cellular kinases, with consequent abnormal hyper-phosphorylation of their target proteins. Therefore, antibodies that allow the detection of phosphorylated versions of proteins have become important tools both preclinically in molecular cancer research, and at the clinical level by serving as tools in pathological analyses of tumors. In order to ensure reliable results, validation of the phospho-specificity of these antibodies is extremely important, since this ensures that they are indeed able to discriminate between the phosphorylated and unphosphorylated versions of the protein of interest, specifically recognizing the phosphorylated variant. A recommended validation approach consists in dephosphorylating the target protein and assessing if such dephosphorylation abrogates antigen immunoreactivity when using the phospho-specific antibody. In this chapter, we describe a protocol to validate the specificity of a phospho-specific antibody that recognizes a phosphorylated variant of the Retinoblastoma (Rb) protein in lung cancer cell lines. The protocol consists in the dephosphorylation of the Rb-containing protein lysates by treating them with bovine intestinal phosphatase, followed by assessment of the dephosphorylation by immunoblot.


  • Open Access

    Creation of Formalin-Fixed, Paraffin-Embedded 3D Lung Cancer Cellular Spheroids for the Optimization of Immunohistochemistry Staining Procedures

    by Jennifer Cabán-Rivera, Camille Chardón-Colón, Alberto Pedraza-Torres, Yoan E. Rodríguez, Raymond Quiñones-Alvarado, Pedro G. Santiago-Cardona

    In an era of precision medicine important treatment decisions are dictated by expression of clinically informative tumor protein biomarkers. These biomarkers can be detected by immunohistochemistry (IHC) performed in tumor tissue sections obtained from biopsies or resections. Like all experimental procedures, IHC needs optimization for several of its steps. However, the investigator must avoid optimizing the IHC procedure using valuable human biopsy samples which may be difficult to obtain. Ideally, valuable biopsy samples should only be subjected to IHC once the IHC protocol has been optimized. In this chapter, we describe a procedure for IHC optimization using tri-dimensional (3D) cellular spheroids created from cultured cells. In this approach, cultured cells are pelleted into 3D spheroids, which are then processed just like a tissue sample, namely, fixed, embedded, sectioned, mounted on slides, and stained with IHC just like a human tissue sample. These 3D cellular spheroids have a tissue-like architecture and cellularity resembling a tumor section, and both cellular and antigen structure are preserved. This method is therefore acceptable for IHC optimization before proceeding to the IHC staining of human tumor samples.


  • Open Access

    Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker

    by Jaileene Pérez-Morales, Darielys Mejías-Morales, Stephanie Rivera-Rivera, Jonathan González-Flores, Mónica González-Loperena, Fernando Y Cordero-Báez, Wilfredo M Pedreira-García, Camille Chardón-Colón, Jennifer Cabán-Rivera, W Douglas Cress, et al.

    Prediction of lung cancer metastasis relies on post-resection assessment of tumor histology, which is a severe limitation since only a minority of lung cancer patients are diagnosed with resectable disease. Therefore, characterization of metastasis-predicting biomarkers in pre-resection small biopsy specimens is urgently needed. Here we report a biomarker consisting of the phosphorylation of the retinoblastoma protein (Rb) on serine 249 combined with elevated p39 expression. This biomarker correlates with epithelial-to-mesenchymal transition traits in non-small cell lung carcinoma (NSCLC) cells. Immunohistochemistry staining of NSCLC tumor microarrays showed that strong phospho-Rb S249 staining positively correlated with tumor grade specifically in the squamous cell carcinoma (SCC) subtype. Strong immunoreactivity for p39 positively correlated with tumor stage, lymph node invasion, and distant metastases, also in SCC. Linear regression analyses showed that the combined scoring for phospho-Rb S249, p39 and E-cadherin in SCC is even more accurate at predicting tumor staging, relative to each score individually. We propose that combined immunohistochemistry staining of NSCLC samples for Rb phosphorylation on S249, p39, and E-cadherin protein expression could aid in the assessment of tumor staging and metastatic potential when tested in small primary tumor biopsies. The intense staining for phospho-Rb S249 that we observed in high grade SCC could also aid in the precise sub-classification of poorly differentiated SCCs.


  • Detection of Retinoblastoma Protein Phosphorylation by Immunoblot Analysis

    by Pedro G. Santiago-Cardona, Jaileene Pérez-Morales, Jonathan González-Flores

    The retinoblastoma tumor suppressor protein (pRb) is a preeminent tumor suppressor that acts as a cell cycle repressor, specifically as an inhibitor of the G1–S transition of the cell cycle. pRb is a phosphoprotein whose function is repressed by extensive phosphorylation in several key residues, and therefore, pRb’s phosphorylation status has become a surrogate for pRb activity. In particular, hyperphosphorylation of pRb has been associated with pathological states such as cancer, and therefore, assessing pRb’s phosphorylation status is increasingly gaining diagnostic and prognostic value, may be used to inform therapeutic decisions, and is also an important tool for the cancer biologists seeking an understanding of the molecular etiology of cancer. In this chapter, we discuss an immunoblot protocol to detect pRb phosphorylation in two residues, serine 612 and threonine 821, in protein extracts from cancer cells.


  • Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients

    by Nicholas T. Gimbrone, Bhaswati Sarcar, Edna R. Gordian, Jason I. Rivera, Christian Lopez, Sean J. Yoder, Jamie K. Teer, Eric A. Welsh, Alberto A. Chiappori, Matthew B. Schabath, et al.


  • Open Access

    The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts

    by Bernadette Sosa-García, Viviana Vázquez-Rivera, Jonathan N. González-Flores, Brienne E. Engel, W. Douglas Cress, Pedro G. Santiago-Cardona

    We previously characterized the retinoblastoma tumor suppressor protein (Rb) as a regulator of adherens junction assembly and cell-to-cell adhesion in osteoblasts. This is a novel function since Rb is predominantly known as a cell cycle repressor. Herein, we characterized the molecular mechanisms by which Rb performs this function, hypothesizing that Rb controls the activity of known regulators of adherens junction assembly. We found that Rb represses the expression of the p21-activated protein kinase (Pak1), an effector of the small Rho GTPase Rac1. Rac1 is a well-known regulator of adherens junction assembly whose increased activity in cancer is linked to perturbations of intercellular adhesion. Using nuclear run-on and luciferase reporter transcription assays, we found that Pak1 repression by Rb is transcriptional, without affecting Pak1 mRNA and protein stability. Pak1 promoter bioinformatics showed multiple E2F1 binding sites within 155 base pairs of the transcriptional start site, and a Pak1-promoter region containing these E2F sites is susceptible to transcriptional inhibition by Rb. Chromatin immunoprecipitations showed that an Rb-E2F complex binds to the region of the Pak1 promoter containing the E2F1 binding sites, suggesting that Pak1 is an E2F target and that the repressive effect of Rb on Pak1 involves blocking the trans-activating capacity of E2F. A bioinformatics analysis showed elevated Pak1 expression in several solid tumors relative to adjacent normal tissue, with both Pak1 and E2F increased relative to normal tissue in breast cancer, supporting a cancer etiology for Pak1 up-regulation. Therefore, we propose that by repressing Pak1 expression, Rb prevents Rac1 hyperactivity usually associated with cancer and related to cytoskeletal derangements that disrupt cell adhesion, consequently enhancing cancer cell migratory capacity. This de-regulation of cell adhesion due to Rb loss could be part of the molecular events associated with cancer progression and metastasis.


  • Open Access

    The retinoblastoma protein: a master tumor suppressor acts as a link between cell cycle and cell adhesion

    by Douglas Cress, Brienne Engel, Pedro G Santiago-Cardona

    RB1 was the first tumor suppressor gene discovered. Over 4 decades of work have revealed that the Rb protein (Rb) is a master regulator of biological pathways influencing virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints, differentiation, senescence, self-renewal, replication, genomic stability, and apoptosis. While these many processes may account for a significant portion of RB1's potency as a tumor suppressor, a small but growing stream of evidence suggests that RB1 also significantly influences how a cell interacts with its environment, including cell-to-cell and cell-to-extracellular matrix interactions. This review will highlight Rb’s role in the control of cell adhesion and how alterations in the adhesive properties of tumor cells may drive the deadly process of metastasis.